Ovarian Cancer section

Ovarian Cancer News & Features

Ovarian cancer oncogene found in 'junk DNA'

Examination of mined junk DNA sequences has helped identify a non-protein-coding RNA whose expression is linked to ovarian cancer.

Olaparib tablet safe in patients with ovarian cancer who received pretreatment

A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.

ACCR: Oral olaparib with chemotherapy beneficial for ovarian cancer

ACCR: Oral olaparib with chemotherapy beneficial for ovarian cancer

Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.

Olaparib tablets safe in patients with relapsed ovarian cancer

Olaparib tablets safe in patients with relapsed ovarian cancer

Olaparib with carboplatin and paclitaxel was found to be safe for the treatment of patients with relapsed ovarian cancer.

Promising results from trial for late-stage peritoneal cancers

A drug originally used to treat ovarian cancer has shown promising results in patients with advanced peritoneal cancers during a phase I clinical trial.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs